Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update ... company incurred in Q3 ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Eli Lilly’s (NYSE: LLY ... grew by 17% and will accelerate in Q4 due to the latest acquisition. Morphic Holding is focused on inflammatory bowel disease, a market worth roughly $22 billion ...

In this example, the acquisition of Morphic in August led to a $3.08 ... This is not a good time to buy Eli Lilly stock, but selling now probably isn't the right move either.

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... in Q3 that were primarily related to its acquisition of Morphic Holding. Without this acquisition, Lilly almost certainly wouldn ...